Comparison of the effect of mutant and wild-type p53 on global gene expression

被引:42
|
作者
O'Farrell, TJ [1 ]
Ghosh, P [1 ]
Dobashi, N [1 ]
Sasaki, CY [1 ]
Longo, DL [1 ]
机构
[1] NIA, Gerontol Res Ctr, Lab Immunol, NIH, Baltimore, MD 21224 USA
关键词
D O I
10.1158/0008-5472.CAN-03-3639
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanisms for "gain-of-function" phenotypes produced by mutant p53s such as enhanced proliferation, resistance to transforming growth factor-beta-mediated growth suppression, and increased tumorigenesis are not known. One theory is that these phenotypes are caused by novel transcriptional regulatory events acquired by mutant p53s. Another explanation is that these effects are a result of an imbalance of functions caused by the retention of some of the wild-type transcriptional regulatory events in the context of a loss of other counterbalancing activities. An analysis of the ability of DNA-binding domain mutants A138P and R175H, and wild-type, p53 to regulate the expression levels of 6.9 x 10(3) genes revealed that the mutants retained only <5% of the regulatory activities of the wild-type protein. A138P p53 exhibited mostly retained wild-type regulatory activities and few acquired novel events. However, R175H p53 possessed an approximately equal number of wild-type regulatory events and novel activities. This is the first report that, after examination of the regulation of a large unfocused set of genes, provides data indicating that remaining wild-type transcriptional regulatory functions existing in the absence of counterbalancing activities as well as acquired novel events both contribute to the gain-of-function phenotypes produced by mutant p53s. However, mutant p53s are likely to be distinct in terms of the extent to which each mechanism contributes to their gain-of-function phenotypes.
引用
收藏
页码:8199 / 8207
页数:9
相关论文
共 50 条
  • [1] COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION
    MILNER, J
    MEDCALF, EA
    [J]. CELL, 1991, 65 (05) : 765 - 774
  • [2] Activities of wild-type and mutant p53
    Vousden, Karen H.
    [J]. CANCER RESEARCH, 2013, 73
  • [3] Osteocalcin Gene Expression Is Regulated by Wild-Type p53
    Chen, Hankui
    Hays, Emily
    Liboon, Jay
    Neely, Chris
    Kolman, Kevin
    Chandar, Nalini
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2011, 89 (05) : 411 - 418
  • [4] Osteocalcin Gene Expression Is Regulated by Wild-Type p53
    Hankui Chen
    Emily Hays
    Jay Liboon
    Chris Neely
    Kevin Kolman
    Nalini Chandar
    [J]. Calcified Tissue International, 2011, 89 : 411 - 418
  • [5] Comparison of mutant and wild-type p53 proteins in Merkel cell carcinoma
    Carson, HJ
    Lueck, NE
    Horten, BC
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, 7 (02) : 326 - 326
  • [6] EXPRESSION OF WILD-TYPE AND MUTANT P53 PROTEINS BY RECOMBINANT VACCINIA VIRUSES
    RONEN, D
    TEITZ, Y
    GOLDFINGER, N
    ROTTER, V
    [J]. NUCLEIC ACIDS RESEARCH, 1992, 20 (13) : 3435 - 3441
  • [7] TUMOR SUPPRESSOR P53 - ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES
    MILNER, J
    MEDCALF, EA
    COOK, AC
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) : 12 - 19
  • [8] Comparison of cellular characteristics between human hepatoma cell lines with wild-type p53 and those with mutant-type p53 gene
    Pu, H
    Tsuji, T
    Kondo, A
    Fushimi, K
    Ohashi, R
    Inoue, Y
    Mimura, T
    Hamazaki, K
    Miyazaki, M
    Namba, M
    [J]. ACTA MEDICA OKAYAMA, 1997, 51 (06) : 313 - 319
  • [9] Modulation of MDR/MRP by wild-type and mutant p53
    Bähr, O
    Wick, W
    Weller, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (05): : 643 - 645
  • [10] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    A Vinyals
    M A Peinado
    M Gonzalez-Garrigues
    M Monzó
    R D Bonfil
    A Fabra
    [J]. Gene Therapy, 1999, 6 : 22 - 33